Unraveling the properties of biological networks is central to understanding both normal and disease cellular phenotypes. Networks consist of functional elements (nodes) that form a variety of diverse connections (edges), with each node being a hub for multiple edges. Herein, in contrast to node-centric network perturbation and analysis approaches, we present a high-throughput CRISPR-based methodology for delineating the role of network edges. Ablation of network edges using a library targeting 93 miRNA target sites in 71 genes reveals numerous edges that control, with variable importance, cellular growth and survival under stress. To compare the impact of removing nodes versus edges in a biological network, we dissect a specific p53-microRNA pathway. We show that removal of the miR-34a target site from the anti-apoptotic gene BCL2 desensitizes the cell to ectopic delivery of miR-34a in a p53-dependent manner. In summary, we demonstrate that network edges are critical to the function and stability of biological networks. Our results introduce a novel genetic screening opportunity via edge ablation and highlight a new dimension in biological network analysis.
Get full access to this article
View all access options for this article.
References
1.
DeLeoAB, JayG, AppellaE, et al.Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A, 1979; 76:2420–2424.
2.
VousdenKH, PrivesC. Blinded by the light: the growing complexity of p53. Cell, 2009; 137:413–431. DOI: 10.1016/j.cell.2009.04.037.
3.
LevineAJ. p53, the cellular gatekeeper for growth and division. Cell, 1997; 88:323–331.
4.
BatchelorE, LoewerA, LahavG. The ups and downs of p53: understanding protein dynamics in single cells. Nat Rev Cancer, 2009; 9:371–377. DOI: 10.1038/nrc2604.
5.
ParralesA, IwakumaT. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol, 2015; 5:28–8. DOI: 10.3389/fonc.2015.00288.
6.
HongB, van den HeuvelAPJ, PrabhuVV, et al.Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets, 2014; 15:80–89.
7.
HeL, HeX, LimLP, et al.A microRNA component of the p53 tumour suppressor network. Nature, 2007; 447:1130–1134. DOI: 10.1038/nature05939.
8.
TarasovV, JungP, VerdoodtB, et al.Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G(1)-arrest. Cell Cycle, 2007; 6:1586–1593. DOI: 10.4161/cc.6.13.4436.
FilipowiczW, BhattacharyyaSN, SonenbergN. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet, 2008; 9:102–114. DOI: 10.1038/nrg2290.
11.
MooreR, OoiHKHK, KangT, et al.MiR-192-mediated positive feedback loop controls the robustness of stress-induced p53 oscillations in breast cancer cells. PLoS Comput Biol, 2015; 11:e100465–3. DOI: 10.1371/journal.pcbi.1004653.
12.
LeeJ, LeeJ, FarquharKS, et al.Network of mutually repressive metastasis regulators can promote cell heterogeneity and metastatic transitions. Proc Natl Acad Sci U S A, 2014; 111:E364–E373. DOI: 10.1073/pnas.1304840111.
13.
AbelsonJF, KwanKY, O'RoakBJ, et al.Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science, 2005; 310:317–320. DOI: 10.1126/science.1116502.
14.
ChatzikyriakidouA, VoulgariPV, GeorgiouI, et al.A polymorphism in the 3′-UTR of interleukin-1 receptor-associated kinase (IRAK1), a target gene of miR-146a, is associated with rheumatoid arthritis susceptibility. Joint Bone Spine, 2010; 77:411–413. DOI: 10.1016/jbspin.2010.05.013.
15.
ConsiglioCR, VeitTD, MonticieloOA, et al.Association of the HLA-G gene +3142C>G polymorphism with systemic lupus erythematosus. Tissue Antigens, 2011; 77:540–545. DOI: 10.1111/j.1399-0039.2011.01635.x.
16.
WuL-S, LiFF, SunLD, et al.A miRNA-492 binding-site polymorphism in BSG (basigin) confers risk to psoriasis in central south Chinese population. Hum Genet, 2011; 130:749–757. DOI: 10.1007/s00449-011.
17.
BrestP, LapaquetteP, SouidiM, et al.A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet, 2011; 43:242–245. DOI: 10.1038/ng.762.
18.
KulkarniS, QiY, O'HuiginC, et al.Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci U S A, 2013; 110:20705–20710. DOI: 10.1073/pnas.1312237110.
19.
WangG, van der WaltJM, MayhewG, et al.Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet, 2008; 82:283–289. DOI: 10.1016/j.ajhg.2007.09.021.
20.
SethupathyP, BorelC, GagnebinM, et al.Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet, 2007; 81:405–413. DOI: 10.1086/519979.
21.
HaninG, Shenhar-TsarfatyS, YayonN, et al.Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet, 2014; 23:4569–4580. DOI: 10.1093/hmg/ddu170.
22.
LvK, GuoY, ZhangY, et al.Allele-specific targeting of hsa-miR-657 to human IGF2R creates a potential mechanism underlying the association of ACAA-insertion/deletion polymorphism with type 2 diabetes. Biochem Biophys Res Commun, 2008; 374:101–105. DOI: 10.1016/j.bbrc.2008.06.102.
23.
RichardsonK, Louie-GaoQ, ArnettDK, et al.The PLIN4 variant rs8887 modulates obesity related phenotypes in humans through creation of a novel miR-522 seed site. PLoS One, 2011; 6:e1794–4. DOI: 10.1371/journal.pone.0017944.
24.
RyanBM, RoblesAI, McClaryAC, et al.Identification of a functional SNP in the 3′UTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res, 2015; 75:566–575. DOI: 10.1158/0008-5472.CAN-14-2101.
25.
ChinLJ, RatnerE, LengS, et al.A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non–small cell lung cancer risk. Cancer Res, 2008; 68. DOI: 10.1158/0008-5472.CAN-08-2129.
26.
ZuY, BanJ, XiaZ, et al.Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun, 2013; 430:529–534. DOI: 10.1016/j.bbrc.2012.12.001.
27.
XiongF, WuC, ChangJ, et al.Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res, 2011; 71:5175–5181. DOI: 10.1158/0008-5472.CAN-10-4407.
28.
PuX, RothJA, HildebrandtMA, et al.MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res, 2013; 73:1867–1875. DOI: 10.1158/00080-5472.CAN-12-0873.
29.
OkadaN, LinC-P, RibeiroMC, et al.A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev, 2014; 28:438–450. DOI: 10.1101/gad.233585.113.
30.
MaliP, YangL, EsveltKM, et al.RNA-guided human genome engineering via Cas9. Science, 2013; 339:823–826. DOI: 10.1126/science.1232033.
31.
RongZ, ZhuS, XuY, et al.Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. Protein Cell, 2014; 5:258–260. DOI: 10.1007/s13238-014-0032-5.
32.
LiJ-F, AachJ, NorvilleJE, et al.Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana via guide RNA/Cas9. Nat Biotechnol, 2013; 31:688–691. DOI: 10.1038/nbt.2654.
33.
WangT, WeiJJ, SabatiniDM, et al.Genetic screens in human cells using the CRISPR-Cas9 system. Science, 2014; 343:80–84. DOI: 10.1126/science.1246981.
34.
ChenS, SanjanaNE, ZhengK, et al.Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell, 2015; 160:1246–1260. DOI: 10.1016/j.cell.2015.02.038.
35.
ZhuS, LiW, ChenCH, et al.Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol, 2016; 34:1279–1286. DOI: 10.1038/nbt.3715.
36.
NavarroF, LiebermanJ. miR-34 and p53: new insights into a complex functional relationship. PLoS One, 2015; 10:e013276–7. DOI: 10.1371/journal.pone.0132767.
37.
SundaramP, HultineS, SmithLM, et al.p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res, 2011; 71:7490–7501. DOI: 10.1158/0008-5472.CAN-11-1124.
ChouC-H, ChangNW, ShresthaS, et al.miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res, 2016; 44:D239–D247. DOI: 10.1093/nar/gkv1258.
40.
AgarwalV, BellGW, NamJ-W, et al.Predicting effective microRNA target sites in mammalian mRNAs. Elife, 2015; 4:e0500–5. DOI: 10.7554/eLife.05005.
41.
SanjanaNE, ShalemO, ZhangF. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods, 2014; 11:783–784. DOI: 10.1038/nmeth.3047.
42.
ShalemO, SanjanaNE, HartenianE, et al.Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 2014; 343:84–87. DOI: 10.1126/science.1247005.
43.
ChangT-C, WentzelEA, KentOA, et al.Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell, 2007; 26:745–752. DOI: 10.1016/j.molcel.2007.05.010.
44.
BaderAG. miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet, 2012; 3:12–0. DOI: 10.1016/j.molcel.2007.05.010.
45.
JiaL, SunY. RBX1/ROC1-SCF E3 ubiquitin ligase is required for mouse embryogenesis and cancer cell survival. Cell Div, 2009; 4:1–6. DOI: 10.1186/1747-1028-4-16.
46.
CoryS, AdamsJM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2002; 2:647–656. DOI: 10.1038/nrc883.
47.
KangT, MooreR, LiY, et al.Discriminating direct and indirect connectivities in biological networks. Proc Natl Acad Sci U S A, 2015; 112:12893–12898.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
